Celyad Oncology SA CLYYF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 4.10K | 4.10K | 7.90K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 4.10K | 4.10K | 7.90K |
| Cost of Revenue | 2.30K | 2.30K | 0.00 | 0.00 | 136.20K |
| Gross Profit | -2.30K | -2.30K | 4.10K | 4.10K | -128.20K |
| SG&A Expenses | 221.00K | 222.30K | 1.22M | 1.23M | 778.00K |
| Depreciation & Amortization | 25.00K | 25.20K | -- | -- | 115.80K |
| Other Operating Expenses | 448.40K | 451.00K | -3.24M | -3.25M | 1.05M |
| Total Operating Expenses | 696.70K | 700.80K | -1.24M | -1.24M | 2.08M |
| Operating Income | -696.70K | -700.80K | 1.24M | 1.24M | -2.07M |
| Income Before Tax | -703.70K | -707.90K | 2.62M | 2.63M | -2.09M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -703.70K | -707.90K | 2.62M | 2.63M | -2.09M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -703.70K | -707.90K | 2.62M | 2.63M | -2.09M |
| EBIT | -696.70K | -700.80K | 1.24M | 1.24M | -2.07M |
| EBITDA | -671.70K | -675.70K | 1.24M | 1.29M | -1.96M |
| EPS Basic | -0.02 | -0.02 | 0.06 | 0.06 | -0.05 |
| Normalized Basic EPS | -0.01 | -0.01 | 0.02 | 0.02 | -0.03 |
| EPS Diluted | -0.02 | -0.02 | 0.05 | 0.05 | -0.05 |
| Normalized Diluted EPS | -0.01 | -0.01 | 0.01 | 0.02 | -0.03 |
| Average Basic Shares Outstanding | 44.76M | 44.76M | 44.13M | 44.13M | 41.40M |
| Average Diluted Shares Outstanding | 44.76M | 44.76M | 51.11M | 51.11M | 41.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |